Gynecologic oncology
Journal
Overview
publication venue for
-
Diagnosis and management of an endometrial cancer patient with Cowden syndrome.
2021
-
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
2019
-
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
2018
-
En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report.
2006
-
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic..
183.
2024
-
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
2024
-
Integration and usability of a digital cancer risk stratification tool to optimize identification of patients at risk for hereditary cancers: A pilot study..
183.
2024
-
Racial disparities in endometrial cancer: Where are we after 26 years?.
184.
2024
-
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)..
182.
2024
-
Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement..
181.
2024
-
Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population..
181.
2023
-
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials..
181.
2023
-
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival..
180.
2023
-
Germline drivers of gynecologic carcinosarcomas..
174.
2023
-
Web-based tool for cancer family history collection: A prospective randomized controlled trial..
173.
2023
-
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management..
170.
2023
-
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study..
169.
2022
-
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis..
166.
2022
-
Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer..
166.
2022
-
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.
2021
-
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy..
163.
2021
-
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial..
162.
2021
-
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study..
162.
2021
-
Underrepresented minority representation trends in gynecologic oncology fellowships in the United States..
160.
2020
-
Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic..
160.
2020
-
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals..
159.
2020
-
Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection..
159.
2020
-
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer..
159.
2020
-
Sexual harassment and gender discrimination in gynecologic oncology..
159.
2020
-
Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study..
159.
2020
-
Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study..
159.
2020
-
A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors..
158.
2020
-
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative..
158.
2020
-
Promoting health equity in the era of COVID-19..
158.
2020
-
Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer..
157.
2020
-
Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression..
157.
2020
-
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer..
157.
2020
-
Primary malignant ovarian carcinoid; management and outcomes..
157.
2020
-
Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma..
156.
2019
-
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study..
156.
2019
-
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer..
156.
2019
-
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer..
156.
2019
-
Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer..
155.
2019
-
Secondary surgical resection for patients with recurrent uterine leiomyosarcoma..
154.
2019
-
Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma..
154.
2019
-
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status..
154.
2019
-
Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center..
154.
2019
-
Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease..
154.
2019
-
Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis..
153.
2019
-
Hospice utilization in advanced cervical malignancies: An analysis of the National Inpatient Sample..
152.
2018
-
Risk-based stratification of carcinomas concurrently involving the endometrium and ovary..
152.
2018
-
A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer..
151.
2018
-
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study..
151.
2018
-
Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment..
151.
2018
-
Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer..
151.
2018
-
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study..
151.
2018
-
Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy..
151.
2018
-
Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?.
151.
2018
-
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer..
150.
2018
-
Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center..
149.
2018
-
An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative..
148.
2018
-
Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers..
148.
2018
-
Fertility-preserving surgery for advanced stage ovarian germ cell tumors..
147.
2017
-
Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery..
147.
2017
-
Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease..
147.
2017
-
Genetic predisposition to bevacizumab-induced hypertension..
147.
2017
-
Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer..
147.
2017
-
Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer..
147.
2017
-
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine..
147.
2017
-
Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base..
147.
2017
-
Endometrial cancer surveillance adherence reduces utilization and subsequent costs..
146.
2017
-
Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery..
147.
2017
-
Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?.
147.
2017
-
Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum..
146.
2017
-
Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes..
146.
2017
-
Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach..
146.
2017
-
Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes..
146.
2017
-
YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy..
145.
2017
-
Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care..
145.
2017
-
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy..
145.
2017
-
Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors..
145.
2017
-
A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer..
145.
2017
-
Primary lymphoma of the female genital tract: An analysis of 697 cases..
145.
2017
-
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?.
145.
2017
-
Potential immunotherapy targets in recurrent cervical cancer..
145.
2017
-
A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer..
145.
2017
-
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study..
145.
2017
-
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study..
144.
2017
-
Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study..
144.
2016
-
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort..
144.
2016
-
Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma..
144.
2016
-
A comparison of two psychological interventions for newly-diagnosed gynecological cancer patients..
144.
2016
-
Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort..
144.
2016
-
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study..
144.
2016
-
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D..
144.
2016
-
Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base..
144.
2016
-
Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study..
143.
2016
-
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis..
143.
2016
-
The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status..
143.
2016
-
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center..
143.
2016
-
Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life..
143.
2016
-
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline..
143.
2016
-
Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy..
143.
2016
-
Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients..
142.
2016
-
Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma..
142.
2016
-
The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer..
142.
2016
-
Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes..
142.
2016
-
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center..
142.
2016
-
Malignant Brenner tumors of the ovary; a population-based analysis..
142.
2016
-
A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease..
142.
2016
-
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study..
141.
2016
-
Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery..
141.
2016
-
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes..
141.
2016
-
Natural history and outcome of neuroendocrine carcinoma of the cervix..
141.
2016
-
Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study..
141.
2016
-
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer..
140.
2016
-
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center..
140.
2016
-
Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer..
140.
2016
-
Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer..
140.
2016
-
Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion..
140.
2015
-
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience..
139.
2015
-
Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening..
139.
2015
-
Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer..
138.
2015
-
Cardiorespiratory fitness in survivors of cervical, endometrial, and ovarian cancers: The Cooper Center Longitudinal Study..
138.
2015
-
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N..
138.
2015
-
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study..
137.
2015
-
Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)..
137.
2015
-
The role of systemic chemotherapy in the management of granulosa cell tumors..
136.
2014
-
Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification..
136.
2014
-
Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis..
136.
2014
-
Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma..
136.
2014
-
A qualitative study of ovarian cancer survivors' perceptions of endpoints and goals of care..
135.
2014
-
Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma..
135.
2014
-
AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer..
135.
2014
-
Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma..
135.
2014
-
A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer..
134.
2014
-
A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer..
134.
2014
-
A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer..
134.
2014
-
Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer..
134.
2014
-
Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study..
134.
2014
-
The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications..
133.
2014
-
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study..
133.
2014
-
Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies..
133.
2014
-
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer..
133.
2014
-
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study..
132.
2014
-
Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer..
132.
2013
-
Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy..
132.
2013
-
Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: a feasibility study..
132.
2013
-
Lymphatic and nerve distribution throughout the parametrium..
131.
2013
-
Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion..
131.
2013
-
Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy..
131.
2013
-
Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity..
131.
2013
-
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer..
130.
2013
-
Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees..
130.
2013
-
Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative..
130.
2013
-
Optimal (≤1 cm) but visible residual disease: is extensive debulking warranted?.
130.
2013
-
Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer..
130.
2013
-
The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration..
129.
2013
-
Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer..
129.
2013
-
Management of uterine adenosarcomas with and without sarcomatous overgrowth..
129.
2012
-
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome..
129.
2012
-
Pelvic insufficiency fractures in patients with cervical and endometrial cancer treated with postoperative pelvic radiation..
128.
2012
-
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study..
129.
2012
-
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173..
128.
2012
-
Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer..
128.
2012
-
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma..
128.
2012
-
Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer..
128.
2012
-
Social-cognitive processes associated with fear of recurrence among women newly diagnosed with gynecological cancers..
128.
2012
-
Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible..
128.
2012
-
A prospective study of quality of life in patients undergoing pelvic exenteration: interim results..
128.
2012
-
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study..
127.
2012
-
Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis..
127.
2012
-
High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes..
127.
2012
-
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma..
126.
2012
-
Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome..
126.
2012
-
Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer..
126.
2012
-
Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis..
125.
2012
-
Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach..
125.
2012
-
Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery..
125.
2012
-
Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer..
125.
2011
-
Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer..
124.
2011
-
Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer..
125.
2011
-
Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies..
125.
2011
-
Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma..
124.
2011
-
Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment..
125.
2011
-
Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma..
124.
2011
-
Pelvic exenteration with curative intent for recurrent uterine malignancies..
124.
2011
-
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study..
124.
2011
-
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer..
124.
2011
-
The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma..
123.
2011
-
Accuracy of frozen section diagnosis of ovarian borderline tumor..
123.
2011
-
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)..
124.
2011
-
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study..
123.
2011
-
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study..
122.
2011
-
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers..
123.
2011
-
The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC)..
123.
2011
-
Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger..
123.
2011
-
Surgical cytoreduction in stage IV endometrioid endometrial carcinoma..
122.
2011
-
New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection..
122.
2011
-
Malignant melanoma of the vulva: an extension of cutaneous melanoma?.
122.
2011
-
Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer..
122.
2011
-
Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes..
122.
2011
-
Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma..
121.
2011
-
Sentinel lymph node biopsy in the management of early-stage cervical carcinoma..
120.
2011
-
"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer..
120.
2010
-
Risk factors for recurrence of ovarian borderline tumors..
120.
2010
-
Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation?.
119.
2010
-
MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion..
120.
2010
-
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors..
120.
2010
-
A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer..
119.
2010
-
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers..
120.
2010
-
Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment..
120.
2010
-
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment..
119.
2010
-
Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors..
119.
2010
-
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers..
119.
2010
-
Lymph nodes: is total number or station number a better predictor of lymph node metastasis in endometrial cancer?.
119.
2010
-
Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: a clinicopathologic study of 84 patients originally classified as FIGO stage II..
119.
2010
-
Cognitive functions in long-term survivors of ovarian cancer..
119.
2010
-
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas..
119.
2010
-
The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm..
118.
2010
-
Use of multimedia as an educational tool to improve human papillomavirus vaccine acceptability--a pilot study..
118.
2010
-
Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer..
117.
2010
-
A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care..
116.
2010
-
The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum..
116.
2010
-
Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series..
117.
2010
-
A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors..
117.
2010
-
Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?.
117.
2010
-
Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy..
117.
2010
-
The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study..
117.
2010
-
Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity..
117.
2010
-
Consolidation strategies in ovarian cancer: observations for future clinical trials..
116.
2010
-
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma..
116.
2009
-
Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients..
116.
2009
-
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment..
116.
2009
-
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors..
116.
2009
-
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study..
116.
2009
-
Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer..
116.
2009
-
Pelvic lymphadenectomy in cervical cancer--surgical anatomy and proposal for a new classification system..
116.
2009
-
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study..
115.
2009
-
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study..
115.
2009
-
Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed?.
115.
2009
-
VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion..
115.
2009
-
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers..
115.
2009
-
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study..
115.
2009
-
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes..
115.
2009
-
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer..
115.
2009
-
Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma..
114.
2009
-
A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery..
114.
2009
-
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm..
114.
2009
-
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies..
113.
2009
-
Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?.
113.
2009
-
Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma..
113.
2009
-
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash..
113.
2009
-
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study..
112.
2009
-
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma..
112.
2009
-
Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy..
112.
2008
-
Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass..
112.
2008
-
Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer..
112.
2008
-
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer..
112.
2008
-
Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study..
112.
2008
-
LPA receptor 2 mediates LPA-induced endometrial cancer invasion..
112.
2008
-
Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes..
112.
2008
-
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease..
111.
2008
-
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study..
111.
2008
-
Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy..
111.
2008
-
Retroperitoneal lymph node dissection (RPLND)..
111.
2008
-
Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy..
111.
2008
-
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma..
111.
2008
-
Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma..
111.
2008
-
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma..
111.
2008
-
Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer..
111.
2008
-
Radical trachelectomy for cervical cancer: postoperative physical and emotional adjustment concerns..
111.
2008
-
What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?.
111.
2008
-
Adjuvant radiation for early stage endometrial cancer with lymphovascular invasion..
111.
2008
-
Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system..
110.
2008
-
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer..
110.
2008
-
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial..
109.
2008
-
S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac..
110.
2008
-
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study..
109.
2008
-
Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era..
109.
2008
-
Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner..
108.
2008
-
Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer..
109.
2008
-
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study..
108.
2008
-
Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series..
108.
2008
-
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer..
108.
2007
-
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer..
108.
2007
-
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer..
108.
2007
-
Initial experience with Dargent's operation: the radical vaginal trachelectomy..
108.
2007
-
Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma..
108.
2007
-
Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis..
107.
2007
-
S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells..
107.
2007
-
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials..
106.
2007
-
Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer..
107.
2007
-
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study..
106.
2007
-
A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model..
107.
2007
-
Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer..
106.
2007
-
Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy..
106.
2007
-
A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration..
106.
2007
-
The role of cytoreductive surgery for colon cancer metastatic to the ovary..
105.
2007
-
Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience..
105.
2007
-
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature..
105.
2007
-
Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches..
105.
2007
-
Reproductive concerns of women treated with radical trachelectomy for cervical cancer..
105.
2006
-
Transperitoneal laparoscopic staging with aortic and pelvic lymph node dissection for gynecologic malignancies..
104.
2006
-
Extended pelvic resection of iliacus muscle and femoral nerve for isolated recurrent uterine cancer..
104.
2006
-
Superior pubic rami resection for isolated recurrent uterine cancer..
104.
2006
-
Radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy for early-stage cervical cancer in patients who desire to preserve fertility..
104.
2006
-
Distal partial gastrectomy and gastrojejunal anastomosis for recurrent ovarian cancer..
104.
2006
-
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma..
104.
2006
-
Hand-assisted laparoscopic splenectomy for isolated ovarian cancer recurrence..
104.
2006
-
Liver mobilization and diaphragm peritonectomy/resection..
104.
2006
-
Schauta radical vaginal hysterectomy..
104.
2006
-
Sentinel lymph node identification for early-stage cervical cancer..
104.
2006
-
The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions..
104.
2006
-
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer..
104.
2006
-
Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis..
104.
2006
-
A new prognostic model for FIGO stage 1 epithelial ovarian cancer..
104.
2006
-
The outcomes of patients with positive margins after excision for intraepithelial Paget's disease of the vulva..
104.
2006
-
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer..
104.
2006
-
Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome..
104.
2006
-
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy..
104.
2006
-
S1P regulation of ovarian carcinoma invasiveness..
103.
2006
-
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer..
103.
2006
-
Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality..
103.
2006
-
Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization..
103.
2006
-
Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum..
103.
2006
-
Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer..
103.
2006
-
Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance..
103.
2006
-
Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy..
103.
2006
-
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center..
103.
2006
-
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?.
103.
2006
-
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study..
103.
2006
-
Salvage cytoreductive surgery for recurrent endometrial cancer..
103.
2006
-
Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary..
103.
2006
-
Surgical resection of recurrent endometrial carcinoma..
102.
2006
-
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning..
102.
2006
-
The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy..
102.
2006
-
Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma..
102.
2006
-
Laparoscopic findings during adnexal surgery in women with a history of nongynecologic malignancy..
101.
2005
-
Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancer..
101.
2005
-
Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma..
101.
2005
-
Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance..
100.
2005
-
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study..
99.
2005
-
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium..
100.
2005
-
Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery..
99.
2005
-
Surgical care of elderly women with ovarian cancer: a population-based perspective..
99.
2005
-
LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2)..
97.
2005
-
Laparoscopic lymphadenectomy for gynecologic malignancies using ultrasonically activated shears: analysis of first 100 cases..
97.
2005
-
Gynecologic cancer treatment and the impact of cancer-related infertility..
97.
2005
-
Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study..
96.
2005
-
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma..
96.
2005
-
Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer..
96.
2005
-
Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis..
96.
2005
-
Evaluation of germline PTEN mutations in endometrial cancer patients..
96.
2005
-
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?.
95.
2004
-
Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group..
95.
2004
-
Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms..
95.
2004
-
The use of colorectal stents for palliation of large-bowel obstruction due to recurrent gynecologic cancer..
95.
2004
-
Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes..
95.
2004
-
Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8..
95.
2004
-
Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma..
95.
2004
-
Tertiary cytoreduction in patients with recurrent ovarian carcinoma..
95.
2004
-
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach..
94.
2004
-
Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience..
94.
2004
-
The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions..
94.
2004
-
Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray..
94.
2004
-
Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation..
94.
2004
-
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma..
93.
2004
-
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians..
93.
2004
-
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer..
93.
2004
-
A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma..
93.
2004
-
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer..
93.
2004
-
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study..
93.
2004
-
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma..
92.
2004
-
Role of laparoscopy in the evaluation of the adnexa in patients with stage IV breast cancer..
92.
2004
-
Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy..
91.
2003
-
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience..
91.
2003
-
Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy..
91.
2003
-
Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus..
91.
2003
-
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy..
91.
2003
-
The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer..
90.
2003
-
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer..
90.
2003
-
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life..
89.
2003
-
Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique..
89.
2003
-
Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series..
89.
2003
-
Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy..
89.
2003
-
Laparoscopic identification of sentinel lymph nodes in early stage cervical cancer: prospective study using a combination of patent blue dye injection and technetium radiocolloid injection..
89.
2003
-
Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma..
87.
2002
-
Craniotomy for central nervous system metastases in epithelial ovarian carcinoma..
87.
2002
-
Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer..
85.
2002
-
Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma..
84.
2002
-
Identification of prognostic factors in advanced epithelial ovarian carcinoma..
82.
2001
-
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients..
82.
2001
-
Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction..
82.
2001
-
Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer..
81.
2001
-
Breast cancer risk assessment in indigent women at a public hospital..
81.
2001
-
Characteristics and survival of cervical cancer patients managed at adjacent urban public and university medical centers..
81.
2001
-
Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer..
81.
2001
-
Complications associated with intraperitoneal chemotherapy catheters..
81.
2001
-
Epithelial ovarian carcinoma and European birthplace of grandparents..
81.
2001
-
High incidence of positive peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal hysterectomy..
80.
2001
-
Risk of endometrial carcinoma associated with BRCA mutation..
80.
2001
-
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube..
80.
2001
-
The role of laparoscopy in second-look evaluations for ovarian cancer..
80.
2001
-
Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences..
79.
2000
-
Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look..
79.
2000
-
Continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for recurrent gynecologic malignancies..
78.
2000
-
The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma..
77.
2000
-
Assessing disease extent in women with bulky or clinically evident metastatic cervical cancer: yield of pretreatment studies..
76.
2000
-
The significance of ASCUS cytology in HIV-positive women..
75.
1999
-
The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasia in HIV-positive women..
74.
1999
-
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer..
73.
1999
-
The accuracy of frozen-section diagnosis in metastatic breast and colorectal carcinoma to the adnexa..
73.
1999
-
Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists..
71.
1998
-
Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study..
70.
1998
-
A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment..
69.
1998
-
Enhanced radiosensitization with interferon-alpha-2b and cisplatin in the treatment of locally advanced cervical carcinoma..
67.
1997
-
Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity..
67.
1997
-
Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer..
67.
1997
-
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up..
67.
1997
-
The role of surgical cytoreduction in Stage IV endometrial carcinoma..
67.
1997
-
Infrared spectroscopy of normal and abnormal cervical smears: evaluation by principal component analysis..
66.
1997
-
Metastatic breast carcinoma to the abdomen and pelvis..
66.
1997
-
Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study..
65.
1997
-
Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction..
64.
1997
-
Intra- and perioperative complications associated with tandem and colpostat application for cervix cancer..
64.
1997
-
Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa..
61.
1996
-
The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma..
61.
1996
-
Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium..
61.
1996
-
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer..
61.
1996
-
A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus..
56.
1995
-
Extramammary Paget's disease of the vulva..
56.
1995
-
Advanced ovarian carcinoma: molecular evidence of unifocal origin..
51.
1993
-
Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer..
51.
1993
-
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer..
50.
1993
-
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma..
50.
1993
-
Impact of age on survival of patients with ovarian cancer..
49.
1993
-
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment..
49.
1993
-
The use of recombinant human erythropoietin to prevent carboplatin-induced anemia..
49.
1993
-
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery..
48.
1993
-
High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodies..
48.
1993
-
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer..
47.
1992
-
Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy..
43.
1991
-
Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube..
42.
1991
-
Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy..
42.
1991
-
Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma..
41.
1991
-
Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system..
41.
1991
-
Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide..
41.
1991
-
Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy..
40.
1991
-
Aggressive chemosurgical debulking in patients with advanced ovarian cancer..
38.
1990
-
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma..
34.
1989
-
Advanced-stage endometrial cancer: contributions of estrogen use, smoking, and other risk factors..
32.
1989
-
Nonoperative supravesical urinary diversion in obstetrics and gynecology..
14.
1982
-
Nuclear magnetic resonance properties of gynecological tissues..
6.
1978
-
Re: "Pelvic exenteration with curative intent for recurrent uterine malignancies"..
126.
2012
-
Re: defining the limits of radical cytoreductive surgery in ovarian cancer..
125.
2012
-
RE: "Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers"..
122.
2011
-
In response to: Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis..
115.
2009
-
Observation on the surgical aspect of resection of noncolorectal nonneuroendocrine hepatic parenchymal metastasis in patients with primary epithelial ovarian carcinoma..
115.
2009
-
Re: "Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials"..
108.
2008
-
Re: "En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report"..
104.
2007
-
A primary ovarian leiomyosarcoma with micro-invasive features (stage I): is surgical excision enough?.
73.
1999
-
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.
2014
-
We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.
2013
-
Proceedings from the 9th International Conference on Ovarian Cancer.
2011
-
National Institutes of Health Consensus Development Conference statement on cervical cancer. April 1-3, 1996.
1997
-
Destigmatizing gynecologic cancers and prioritizing prospective radiotherapy studies..
182.
2024
-
Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approach..
172.
2023
-
Novel therapy in endometrial cancer: How much will we pay?.
162.
2021
-
State of the science: Uterine sarcomas: From pathology to practice..
159.
2020
-
Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?.
157.
2020
-
Coronavirus concerns: What do women with gynecologic cancer need to know during the COVID-19 crisis?.
158.
2020
-
A call to standardize our approach to fertility-sparing surgery in patients with gynecologic cancers..
147.
2017
-
Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there"..
147.
2017
-
Venous thromboembolism and minimally invasive surgery in gynecologic oncology: time to re-evaluate and refocus..
134.
2014
-
Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force..
124.
2011
-
Novel diagnostic and therapeutic approaches in Gynecologic Oncology: considerations for a new decade..
120.
2011
-
Advances in the management of endometrial carcinoma..
120.
2011
-
Options in the management of fertility-related issues after radical trachelectomy in patients with early cervical cancer..
114.
2009
-
Investigating women with suspected ovarian cancer..
108.
2007
-
Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy..
106.
2007
-
Surgical postgraduate courses. Gynecologic oncology. Introduction..
104.
2006
-
The role of bevacizumab in ovarian cancer--an evolving story..
102.
2006
-
CO(2) pneumoperitoneum or the Bookwalter: choose your access and exposure..
97.
2005
-
Is observation and salvage (when necessary) an appropriate approach to intermediate risk endometrial cancer?.
89.
2003
-
Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma?.
77.
2000
-
Clarity and confusion regarding adjuvant radiation therapy in early endometrial cancer..
75.
1999
-
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
2021
-
It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
2018
-
The roles of pathology in targeted therapy of women with gynecologic cancers.
2017
-
Indications for and complications of transfusion and the management of gynecologic malignancies.
2017
-
Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide.
2015
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
2015
-
Treatment of ovarian cancer in the older woman.
2014
-
Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.
2014
-
Fertility considerations in the management of gynecologic malignancies.
2010
-
A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer.
2009
-
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
2008
-
Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.
2006
-
Role of pegylated liposomal doxorubicin in ovarian cancer.
2005
-
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
2004
-
Computed tomography guided core needle biopsy diagnosis of pelvic actinomycosis.
2000
-
Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
2023
-
Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
2023
-
Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review.
2022
-
Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis.
2016
-
Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document.
2011
-
General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer.
2003
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)